European Journal of Cancer
Volume 43, Issue 16 , Pages 2351-2358 , November 2007

A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer – GABG-IV B-93

  • Manfred Kaufmann

      Affiliations

    • Universitäts-Frauenklinik, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany
    • Corresponding Author InformationCorresponding author: Tel.: +49 69 63 01 51 15; fax: +49 69 63 01 63 17.
    • ,
  • Erika Graf

      Affiliations

    • Medizinische Biometrie und Statistik, Universitätsklinikum Freiburg, Freiburg 79098, Germany
    • ,
  • Walter Jonat

      Affiliations

    • Universitäts-Frauenklinik, Kiel 24103, Germany
    • ,
  • Wolfgang Eiermann

      Affiliations

    • Rot-Kreuz-Krankenhaus, München 80331, Germany
    • ,
  • Sabine Vescia

      Affiliations

    • City Hospital, Hanau 63450, Germany
    • ,
  • Matthias Geberth

      Affiliations

    • Onkologische Praxis, Mannheim 68159, Germany
    • ,
  • Bettina Conrad

      Affiliations

    • Senologisches Zentrum, Kassel 34117, Germany
    • ,
  • Günther Gademann

      Affiliations

    • Universitätsklinikum, Magdeburg 39104, Germany
    • ,
  • Ute-Susann Albert

      Affiliations

    • Universitäts-Frauenklinik, Marburg 35037, Germany
    • ,
  • Sibylle Loibl

      Affiliations

    • Universitäts-Frauenklinik, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany
    • German Adjuvant Breast Cancer Study Group (GABG), 60596 Frankfurt, Germany
    • ,
  • Gunter von Minckwitz

      Affiliations

    • Universitäts-Frauenklinik, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany
    • German Adjuvant Breast Cancer Study Group (GABG), 60596 Frankfurt, Germany
    • ,
  • Martin Schumacher

      Affiliations

    • Medizinische Biometrie und Statistik, Universitätsklinikum Freiburg, Freiburg 79098, Germany
    • ,
  • for the German Adjuvant Breast Cancer Study Group (GABG)

      Affiliations

    • German Breast Group (GBG), Neu-Isenburg 63263, Germany

Received 27 April 2007 ,Revised 16 July 2007 ,Accepted 7 August 2007.

References 

  1. Early Breast Cancer Trialists’ Collaborative Group . Systemic treatment of early breast cancer by normal, cytotoxic or immune therapy: 133 randomised trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. Lancet. 1992;339:71–85
  2. Scottish Cancer Trials Breast Group and ICRF Breast Unit . Adjuvant pathological stage II breast carcinoma: The Scottish trial. Lancet. 1993;341:1293–1298
  3. Early Breast Cancer Trialists’ Collaborative Group . Ovarian ablation in early breast cancer. Cochrane Database Syst Rev. 2000;2:[CD000485]
  4. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24:5769–5779
  5. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20:4628–4635
  6. Pagani O, O’Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the Interntional Breast Cancer Study Group (IBCSG) Trial VI:. Eur J Cancer. 1998;34:632–640
  7. Kaufmann M, Jonat W, Schachner-Wünschmann E, Bastert G, Mass H on behalf of the Cooperative German Zoladex Study Group. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer-a 5-year experience and further endocrine therapies. Onkologie. 1991;14:22–30
  8. Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol. 1989;7:1113–1119
  9. Boccardo F, Rubagotti A, Perrotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-/perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol. 1994;5:337–342
  10. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20:4621–4627
  11. Castiglione-Gertsch M, O’Neill A, Price KN, et al. International Breast Cancer Study Group (IBCSG): Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Nat Cancer Inst. 2003;95:1833–1846
  12. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–140
  13. Schmoor C, Olschewski M, Sauerbrei W, Schumacher M. Long-term follow-up of patients in four prospective studies of the German Breast Cancer Study Group (GBSG): A summary of key results. Onkologie. 2002;25:143–150
  14. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499–503
  15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481
  16. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Cont Clin Trials. 1996;17:343–346
  17. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310
  18. Cox DR. Regression models and life table (with discussion). J R Stat Soc B. 1972;34:187–220
  19. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980;
  20. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–663
  21. SAS Institute Inc, SAS language, Version 6. NC, USA: Cary; 1990.
  22. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP Study. Eur J Cancer. 2006;42:895–904
  23. Early Breast Cancer Trialists’ Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717
  24. LHRH-Agonist in Early Breast Cancer Overview GroupCuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–1723
  25. Davidson NE, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor positive breast cancer: results from INT-0101(E5188). J Clin Oncol. 2005;25:5973–5982
  26. Arriagada R, Le MG, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol. 2005;16:389–396
  27. Von Minckwitz G, Graf E, Geberth M, et al. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG-IV-A-93 Trial. Eur J Cancer. 2006;42:1780–1788
  28. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064–1069
  29. Ejlertsen B, Mouridsen HT, Jensen MB, et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol. 2006;24:4956–4962
  30. Pater JL, Parulekar WR. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer – another step forward. J Nat Cancer Inst. 2003;95:1811–1812

☆ The results of this study have been presented in part at the meeting of the American Society of Clinical Oncology in New Orleans, 2004.

PII: S0959-8049(07)00644-2

doi: 10.1016/j.ejca.2007.08.012

European Journal of Cancer
Volume 43, Issue 16 , Pages 2351-2358 , November 2007

Article Tools

* Image Usage & Resolution